MedTrace Logo

Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients

NCT06973382 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-05-15

No results posted yet for this study

Summary

Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.

Conditions

Interventions

BEHAVIORAL

Comprehensive Pulmonary Rehabilitation Program

Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks Session Structure: * 5-minute warm-up * Continuous or interval training (15-30 minutes) * 5-minute cool-downesistance Exercise Component Mode: Dumbbell exercises + cycle ergometry Frequency: 3 sessions per week Program Duration: 12 weeks Session Structure: * 5-minute warm-up * Training session (10-20 minutes) * 5-minute cool-down

BEHAVIORAL

Standard Pulmonary Rehabilitation

xercise Components: Aerobic Exercise Mode: Walking or jogging Resistance Exercise Mode: Elastic bands or dumbbells Training Parameters: Session Duration: ≥35 minutes (combined aerobic + resistance) Frequency: 3-5 sessions per week Program Duration: 12 weeks

Sponsors & Collaborators

  • Beijing Municipal Health Commission

    collaborator OTHER_GOV

  • Beijing Chao Yang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2027-10-31
Completion
2027-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06973382 on ClinicalTrials.gov